Description
Neratinib is an irreversible EGFR inhibitor that displays anticancer chemotherapeutic benefit in the treatment of HER2 positive breast cancers and non-small cell lung cancer (NSCLC). Neratinib prevents ligand-induced receptor dimerization by targeting a cysteine residue in the ATP binding pocket of the receptor. In pre-clinical models, this compound induces cell cycle arrest and decreases cell proliferation.